Claims
- 1. A method of inducing a diuretic effect in a mammal, comprising administration of a therapeutically effective amount of BG9719, or salts or esters thereof in combination with a non-adenosine modifying diuretic.
- 2. The method of claim 1, wherein a therapeutically effective amount of BG9719, or salts or esters thereof, is administered in combination with a non-adenosine modifying diuretic chosen from the group consisting of hydrochlorothiazides, furosemide, torsumide, bumetanide, thacrynic acid, piretanide, norsemide, spironolactone, triamterene, and amiloridethiazides.
- 3. The method of claim 2, wherein the non-adenosine modifying diuretic is furosemide.
- 4. The method of claim 3, wherein the furosemide is administered before BG9719.
- 5. The method of claim 3, wherein the furosemide is administered after BG9719.
- 6. The method of claim 3, wherein the furosemide is administered substantially simultaneously with BG9719.
- 7. The method of claim 2, wherein the mammal is refractory to a diuretic.
- 8. A method of maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic in a patient comprising the administration of a therapeutically effective amount of BG9719, or salts or esters thereof, in combination with said non-adenosine modifying diuretic.
- 9. The method of claim 8, wherein the non-adenosine modifying diuretic is chosen from the group consisting of hydrochlorothiazides, furosemide, torsumide, bumetanide, thacrynic acid, piretanide, norsemide, spironolactone, triamterene, and amiloridethiazides.
- 10. The method of claim 9, wherein the non-adenosine modifying diuretic is furosemide.
- 11. The method of claim 10, wherein the furosemide is administered before BG9719.
- 12. The method of claim 10, wherein the furosemide is administered after BG9719.
- 13. The method of claim 10, wherein the furosemide is administered substantially simultaneously with BG9719.
- 14. A method of maintaining or restoring renal function in a patient comprising the step of administering a therapeutically effective amount of BG9719, or salts or esters thereof, in combination with a non-adenosine modifying diuretic.
- 15. The method of claim 14, wherein the non-adenosine modifying diuretic is chosen from the group consisting of hydrochlorothiazides, furosemide, torsumide, bumetanide, thacrynic acid, piretanide, norsemide, spironolactone, triamterene, and amiloridethiazides.
- 16. The method of claim 15, wherein the non-adenosine modifying diuretic is furosemide.
- 17. The method of claim 16, wherein the furosemide is administered before BG9719.
- 18. The method of claim 16, wherein the furosemide is administered after BG9719.
- 19. The method of claim 16, wherein the furosemide is administered substantially simultaneously with BG9719.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation of U.S. application Ser. No. 09/861,873, filed May 21, 2001 that is a continuation of U.S. application Ser. No. 09/470,068, filed Dec. 22, 1999 that claims the benefit of PCT Application Ser. No. PCT/US99/08879, filed Apr. 23, 1999 that claims the benefit of U.S. Provisional Application Ser. No. 60/083,022, filed Apr. 24, 1998 and U.S. Provisional Application Ser. No. 60/083,638, filed Apr. 30, 1998; the contents of which are incorporated by reference herein in their entirety.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5446046 |
Belardinelli et al. |
Aug 1995 |
A |
Non-Patent Literature Citations (1)
Entry |
Gellai et al., “CVT-124, a Novel Adenosine A1 Receptor Antagonist with Unique Diuretic Activity”, J. Pharmacol. Exp. Ther. (1998), 286(3), pp. 1191-1196. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/083638 |
Apr 1998 |
US |
|
60/083022 |
Apr 1998 |
US |
Continuations (3)
|
Number |
Date |
Country |
Parent |
09/861873 |
May 2001 |
US |
Child |
10/150501 |
|
US |
Parent |
09/470068 |
Dec 1999 |
US |
Child |
09/861873 |
|
US |
Parent |
PCT/US99/08879 |
Apr 1999 |
US |
Child |
09/470068 |
|
US |